SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2ac5'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1Q97_B_ADNB486_1 (SR PROTEIN KINASE)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 4	VAL A 98 ALA A 111 LEU A 143 PHE A 159	None	0.36A	1q97B-2ac5A: 20.8	1q97B-2ac5A: 24.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1S8F_A_BEZA1501_0 (RAS-RELATED PROTEIN RAB-9A)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 5	ILE A 345 TRP A 334 LEU A 349 PRO A 294	None	1.17A	1s8fA-2ac5A: 0.0 1s8fB-2ac5A: 0.0	1s8fA-2ac5A: 18.61 1s8fB-2ac5A: 18.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_A_B49A1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	6 / 12	VAL A 98 ALA A 111 PHE A 159 MET A 162 GLY A 165 LEU A 212	None	0.59A	2y7jA-2ac5A: 27.0	2y7jA-2ac5A: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	6 / 10	VAL A 98 ALA A 111 PHE A 159 MET A 162 GLY A 165 LEU A 212	None	0.63A	2y7jB-2ac5A: 20.5	2y7jB-2ac5A: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_C_B49C1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	6 / 10	VAL A 98 ALA A 111 PHE A 159 MET A 162 GLY A 165 LEU A 212	None	0.63A	2y7jC-2ac5A: 27.1	2y7jC-2ac5A: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_D_B49D1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	6 / 10	VAL A 98 ALA A 111 PHE A 159 MET A 162 GLY A 165 LEU A 212	None	0.64A	2y7jD-2ac5A: 27.0	2y7jD-2ac5A: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2YFX_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 8	ALA A 111 MET A 162 GLY A 165 LEU A 212	None	0.51A	2yfxA-2ac5A: 19.8	2yfxA-2ac5A: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GP0_A_NILA1_2 (MITOGEN-ACTIVATED PROTEIN KINASE 11)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 7	LYS A 113 VAL A 142 MET A 162 ILE A 224	None	0.88A	3gp0A-2ac5A: 20.5	3gp0A-2ac5A: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GP0_A_NILA1_2 (MITOGEN-ACTIVATED PROTEIN KINASE 11)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 7	VAL A 142 LEU A 157 MET A 162 ILE A 224	None	0.73A	3gp0A-2ac5A: 20.5	3gp0A-2ac5A: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEG_A_BAXA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	7 / 12	VAL A 89 VAL A 98 ALA A 111 LYS A 113 GLU A 129 LEU A 133 ILE A 201	None	1.29A	3hegA-2ac5A: 17.3	3hegA-2ac5A: 27.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEG_A_BAXA1_2 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	VAL A 142 ILE A 201 HIS A 203 ILE A 224	None	0.47A	3hegA-2ac5A: 17.3	3hegA-2ac5A: 27.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3I9J_B_NCAB302_0 (ADP-RIBOSYL CYCLASE)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	LEU A 168 GLU A 209 ASN A 210 SER A 169	None	1.49A	3i9jB-2ac5A: undetectable	3i9jB-2ac5A: 19.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 9	ALA A 111 PHE A 159 MET A 162 GLY A 165 LEU A 212	None	0.62A	3miyB-2ac5A: 20.6	3miyB-2ac5A: 26.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RF4_A_FUNA201_1 (MACROPHAGE MIGRATION INHIBITORY FACTOR)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 11	SER A 166 ILE A 167 VAL A 222 VAL A 185 ILE A 224	None	1.25A	3rf4A-2ac5A: undetectable 3rf4C-2ac5A: undetectable	3rf4A-2ac5A: 16.72 3rf4C-2ac5A: 16.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RF4_B_FUNB202_1 (MACROPHAGE MIGRATION INHIBITORY FACTOR)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 11	ILE A 224 SER A 166 ILE A 167 VAL A 222 VAL A 185	None	1.20A	3rf4A-2ac5A: undetectable 3rf4B-2ac5A: undetectable	3rf4A-2ac5A: 16.72 3rf4B-2ac5A: 16.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RF4_C_FUNC203_1 (MACROPHAGE MIGRATION INHIBITORY FACTOR)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 11	ILE A 224 SER A 166 ILE A 167 VAL A 222 VAL A 185	None	1.18A	3rf4B-2ac5A: undetectable 3rf4C-2ac5A: undetectable	3rf4B-2ac5A: 16.72 3rf4C-2ac5A: 16.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_1 (CYCLIN-DEPENDENT KINASE 8)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	7 / 12	VAL A 98 ALA A 111 GLU A 129 LEU A 133 PHE A 159 LEU A 196 HIS A 203	None	0.81A	3rgfA-2ac5A: 20.2	3rgfA-2ac5A: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_2 (CYCLIN-DEPENDENT KINASE 8)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 7	LYS A 113 VAL A 142 LEU A 212 ASP A 226	None	0.92A	3rgfA-2ac5A: 20.2	3rgfA-2ac5A: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	7 / 12	VAL A 98 ALA A 111 LYS A 113 LEU A 157 MET A 162 GLY A 165 LEU A 212	None	0.94A	3ug2A-2ac5A: 19.2	3ug2A-2ac5A: 25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZE_A_BAXA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 8	VAL A 142 LEU A 212 ILE A 224 CYH A 225	None	0.64A	3wzeA-2ac5A: 19.5	3wzeA-2ac5A: 25.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 12	ALA A 111 LEU A 143 MET A 162 GLY A 165 LEU A 212	None	0.46A	3zbfA-2ac5A: 20.1	3zbfA-2ac5A: 25.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4G10_A_ACTA301_0 (GLUTATHIONE S-TRANSFERASE HOMOLOG)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	PRO A 330 ILE A 337 TYR A 292 TYR A 286	None	0.94A	4g10A-2ac5A: undetectable	4g10A-2ac5A: 21.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	VAL A 98 ALA A 111 LEU A 143 LEU A 212	None	0.68A	4o0uA-2ac5A: 8.2	4o0uA-2ac5A: 29.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OU1_A_BEZA302_0 (RETRO-ALDOLASE, DESIGN RA114)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 8	ILE A 211 ILE A 224 ASN A 141 ALA A 192	None	0.87A	4ou1A-2ac5A: undetectable	4ou1A-2ac5A: 20.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QRC_A_0LIA802_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 8	VAL A 98 LYS A 113 HIS A 203 LEU A 212	None	0.71A	4qrcA-2ac5A: 19.5	4qrcA-2ac5A: 24.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	7 / 12	ALA A 111 LYS A 113 GLY A 165 HIS A 203 LEU A 212 CYH A 225 ASP A 226	None	0.93A	4u0iA-2ac5A: 19.2	4u0iA-2ac5A: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	7 / 12	ALA A 111 LYS A 113 LEU A 133 GLY A 165 HIS A 203 LEU A 212 CYH A 225	None	0.86A	4u0iA-2ac5A: 19.2	4u0iA-2ac5A: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	6 / 12	VAL A 98 ALA A 111 MET A 132 LEU A 196 HIS A 203 ASP A 226	None	1.00A	4v04A-2ac5A: 19.0	4v04A-2ac5A: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	6 / 12	VAL A 98 GLU A 129 MET A 132 LEU A 196 HIS A 203 ASP A 226	None	1.25A	4v04A-2ac5A: 19.0	4v04A-2ac5A: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	7 / 12	VAL A 98 ALA A 111 LYS A 113 MET A 162 GLY A 165 ASN A 210 LEU A 212	None	0.75A	4wa9B-2ac5A: 20.4	4wa9B-2ac5A: 24.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XOY_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	ALA A 360 GLN A 361 LEU A 363 LEU A 278	None	1.10A	4xoyA-2ac5A: 20.9	4xoyA-2ac5A: 25.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ZAU_A_YY3A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 8	GLY A 91 VAL A 98 ALA A 111 MET A 162 GLY A 165	None	0.85A	4zauA-2ac5A: 19.9	4zauA-2ac5A: 25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ZJ8_A_SUVA2001_2 (HUMAN OX1R FUSION PROTEIN TO P.ABYSII GLYCOGEN SYNTHASE)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	TRP A 334 ILE A 345 ILE A 211 VAL A 189	None	0.93A	4zj8A-2ac5A: undetectable	4zj8A-2ac5A: 20.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CDP_H_EVPH2101_1 (DNA GYRASE SUBUNIT A DNA GYRASE SUBUNIT B)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 6	GLY A 91 ASP A 88 ARG A 97 GLY A 93	None	0.94A	5cdpA-2ac5A: 4.5 5cdpB-2ac5A: undetectable	5cdpA-2ac5A: 21.06 5cdpB-2ac5A: 22.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TE8_C_08JC602_1 (CYTOCHROME P450 3A4)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	4 / 7	LEU A 278 ALA A 190 ILE A 224 LEU A 206	None	0.92A	5te8C-2ac5A: undetectable	5te8C-2ac5A: 20.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5UAC_C_RFPC3001_1 (DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	5 / 12	PHE A 195 ASP A 194 HIS A 197 SER A 270 ILE A 271	None	1.46A	5uacC-2ac5A: 0.7	5uacC-2ac5A: 13.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6EXI_A_ADNA502_1 (ADENOSYLHOMOCYSTEINA SE)	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	3 / 3	LEU A 288 ASN A 141 LEU A 206	None	0.66A	6exiA-2ac5A: undetectable	6exiA-2ac5A: 13.29

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1Q97_B_ADNB486_1","SR PROTEIN KINASE","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"VAL A  98;ALA A 111;LEU A 143;PHE A 159","None","0.36A","1q97B-2ac5A:20.8","1q97B-2ac5A:24.26"],["1S8F_A_BEZA1501_0","RAS-RELATED PROTEIN RAB-9A","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"ILE A 345;TRP A 334;LEU A 349;PRO A 294","None","1.17A","1s8fA-2ac5A:0.0;1s8fB-2ac5A:0.0","1s8fA-2ac5A:18.61;1s8fB-2ac5A:18.61"],["2Y7J_A_B49A1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",6,"VAL A  98;ALA A 111;PHE A 159;MET A 162;GLY A 165;LEU A 212","None","0.59A","2y7jA-2ac5A:27.0","2y7jA-2ac5A:29.18"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",6,"VAL A  98;ALA A 111;PHE A 159;MET A 162;GLY A 165;LEU A 212","None","0.63A","2y7jB-2ac5A:20.5","2y7jB-2ac5A:29.18"],["2Y7J_C_B49C1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",6,"VAL A  98;ALA A 111;PHE A 159;MET A 162;GLY A 165;LEU A 212","None","0.63A","2y7jC-2ac5A:27.1","2y7jC-2ac5A:29.18"],["2Y7J_D_B49D1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",6,"VAL A  98;ALA A 111;PHE A 159;MET A 162;GLY A 165;LEU A 212","None","0.64A","2y7jD-2ac5A:27.0","2y7jD-2ac5A:29.18"],["2YFX_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"ALA A 111;MET A 162;GLY A 165;LEU A 212","None","0.51A","2yfxA-2ac5A:19.8","2yfxA-2ac5A:24.56"],["3GP0_A_NILA1_2","MITOGEN-ACTIVATED PROTEIN KINASE 11","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"LYS A 113;VAL A 142;MET A 162;ILE A 224","None","0.88A","3gp0A-2ac5A:20.5","3gp0A-2ac5A:28.88"],["3GP0_A_NILA1_2","MITOGEN-ACTIVATED PROTEIN KINASE 11","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"VAL A 142;LEU A 157;MET A 162;ILE A 224","None","0.73A","3gp0A-2ac5A:20.5","3gp0A-2ac5A:28.88"],["3HEG_A_BAXA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",7,"VAL A  89;VAL A  98;ALA A 111;LYS A 113;GLU A 129;LEU A 133;ILE A 201","None","1.29A","3hegA-2ac5A:17.3","3hegA-2ac5A:27.47"],["3HEG_A_BAXA1_2","MITOGEN-ACTIVATED PROTEIN KINASE 14","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"VAL A 142;ILE A 201;HIS A 203;ILE A 224","None","0.47A","3hegA-2ac5A:17.3","3hegA-2ac5A:27.47"],["3I9J_B_NCAB302_0","ADP-RIBOSYL CYCLASE","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"LEU A 168;GLU A 209;ASN A 210;SER A 169","None","1.49A","3i9jB-2ac5A:undetectable","3i9jB-2ac5A:19.58"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"ALA A 111;PHE A 159;MET A 162;GLY A 165;LEU A 212","None","0.62A","3miyB-2ac5A:20.6","3miyB-2ac5A:26.71"],["3RF4_A_FUNA201_1","MACROPHAGE MIGRATION INHIBITORY FACTOR;MACROPHAGE MIGRATION INHIBITORY FACTOR","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"SER A 166;ILE A 167;VAL A 222;VAL A 185;ILE A 224","None","1.25A","3rf4A-2ac5A:undetectable;3rf4C-2ac5A:undetectable","3rf4A-2ac5A:16.72;3rf4C-2ac5A:16.72"],["3RF4_B_FUNB202_1","MACROPHAGE MIGRATION INHIBITORY FACTOR;MACROPHAGE MIGRATION INHIBITORY FACTOR","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"ILE A 224;SER A 166;ILE A 167;VAL A 222;VAL A 185","None","1.20A","3rf4A-2ac5A:undetectable;3rf4B-2ac5A:undetectable","3rf4A-2ac5A:16.72;3rf4B-2ac5A:16.72"],["3RF4_C_FUNC203_1","MACROPHAGE MIGRATION INHIBITORY FACTOR;MACROPHAGE MIGRATION INHIBITORY FACTOR","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"ILE A 224;SER A 166;ILE A 167;VAL A 222;VAL A 185","None","1.18A","3rf4B-2ac5A:undetectable;3rf4C-2ac5A:undetectable","3rf4B-2ac5A:16.72;3rf4C-2ac5A:16.72"],["3RGF_A_BAXA465_1","CYCLIN-DEPENDENT KINASE 8","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",7,"VAL A  98;ALA A 111;GLU A 129;LEU A 133;PHE A 159;LEU A 196;HIS A 203","None","0.81A","3rgfA-2ac5A:20.2","3rgfA-2ac5A:25.06"],["3RGF_A_BAXA465_2","CYCLIN-DEPENDENT KINASE 8","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"LYS A 113;VAL A 142;LEU A 212;ASP A 226","None","0.92A","3rgfA-2ac5A:20.2","3rgfA-2ac5A:25.06"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",7,"VAL A  98;ALA A 111;LYS A 113;LEU A 157;MET A 162;GLY A 165;LEU A 212","None","0.94A","3ug2A-2ac5A:19.2","3ug2A-2ac5A:25.95"],["3WZE_A_BAXA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"VAL A 142;LEU A 212;ILE A 224;CYH A 225","None","0.64A","3wzeA-2ac5A:19.5","3wzeA-2ac5A:25.67"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"ALA A 111;LEU A 143;MET A 162;GLY A 165;LEU A 212","None","0.46A","3zbfA-2ac5A:20.1","3zbfA-2ac5A:25.14"],["4G10_A_ACTA301_0","GLUTATHIONE S-TRANSFERASE HOMOLOG","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"PRO A 330;ILE A 337;TYR A 292;TYR A 286","None","0.94A","4g10A-2ac5A:undetectable","4g10A-2ac5A:21.17"],["4O0U_A_ADNA501_1","AURORA KINASE A","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"VAL A  98;ALA A 111;LEU A 143;LEU A 212","None","0.68A","4o0uA-2ac5A:8.2","4o0uA-2ac5A:29.36"],["4OU1_A_BEZA302_0","RETRO-ALDOLASE, DESIGN RA114","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"ILE A 211;ILE A 224;ASN A 141;ALA A 192","None","0.87A","4ou1A-2ac5A:undetectable","4ou1A-2ac5A:20.90"],["4QRC_A_0LIA802_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"VAL A  98;LYS A 113;HIS A 203;LEU A 212","None","0.71A","4qrcA-2ac5A:19.5","4qrcA-2ac5A:24.27"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",7,"ALA A 111;LYS A 113;GLY A 165;HIS A 203;LEU A 212;CYH A 225;ASP A 226","None","0.93A","4u0iA-2ac5A:19.2","4u0iA-2ac5A:25.07"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",7,"ALA A 111;LYS A 113;LEU A 133;GLY A 165;HIS A 203;LEU A 212;CYH A 225","None","0.86A","4u0iA-2ac5A:19.2","4u0iA-2ac5A:25.07"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",6,"VAL A  98;ALA A 111;MET A 132;LEU A 196;HIS A 203;ASP A 226","None","1.00A","4v04A-2ac5A:19.0","4v04A-2ac5A:26.06"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",6,"VAL A  98;GLU A 129;MET A 132;LEU A 196;HIS A 203;ASP A 226","None","1.25A","4v04A-2ac5A:19.0","4v04A-2ac5A:26.06"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",7,"VAL A  98;ALA A 111;LYS A 113;MET A 162;GLY A 165;ASN A 210;LEU A 212","None","0.75A","4wa9B-2ac5A:20.4","4wa9B-2ac5A:24.13"],["4XOY_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"ALA A 360;GLN A 361;LEU A 363;LEU A 278","None","1.10A","4xoyA-2ac5A:20.9","4xoyA-2ac5A:25.47"],["4ZAU_A_YY3A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"GLY A  91;VAL A  98;ALA A 111;MET A 162;GLY A 165","None","0.85A","4zauA-2ac5A:19.9","4zauA-2ac5A:25.95"],["4ZJ8_A_SUVA2001_2","HUMAN OX1R FUSION PROTEIN TO P.ABYSII GLYCOGEN SYNTHASE","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"TRP A 334;ILE A 345;ILE A 211;VAL A 189","None","0.93A","4zj8A-2ac5A:undetectable","4zj8A-2ac5A:20.18"],["5CDP_H_EVPH2101_1","DNA GYRASE SUBUNIT A;DNA GYRASE SUBUNIT B","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"GLY A  91;ASP A  88;ARG A  97;GLY A  93","None","0.94A","5cdpA-2ac5A:4.5;5cdpB-2ac5A:undetectable","5cdpA-2ac5A:21.06;5cdpB-2ac5A:22.01"],["5TE8_C_08JC602_1","CYTOCHROME P450 3A4","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",4,"LEU A 278;ALA A 190;ILE A 224;LEU A 206","None","0.92A","5te8C-2ac5A:undetectable","5te8C-2ac5A:20.25"],["5UAC_C_RFPC3001_1","DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",5,"PHE A 195;ASP A 194;HIS A 197;SER A 270;ILE A 271","None","1.46A","5uacC-2ac5A:0.7","5uacC-2ac5A:13.60"],["6EXI_A_ADNA502_1","ADENOSYLHOMOCYSTEINASE","2ac5","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","Homo sapiens",3,"LEU A 288;ASN A 141;LEU A 206","None","0.66A","6exiA-2ac5A:undetectable","6exiA-2ac5A:13.29"]]